美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Global Partners Lp

43.91

-1.0450-2.32%

成交量：2.94萬

成交額：130.29萬

市值：14.93億

市盈率：16.88

高：45.15

開：45.15

低：43.86

收：44.95

52周最高：60.00

52周最低：43.20

股本：3,399.56萬

流通股本：2,767.42萬

量比：0.53

換手率：0.11%

股息：2.97

股息率：6.76%

每股收益(TTM):2.60

每股收益(LYR):2.45

淨資產收益率：16.33%

總資產收益率：4.09%

市淨率：2.44

市盈率(LYR):17.95

資料載入中...

總覽公司新聞公告

GLP-1黑馬遞表港股IPO，上輪投後估值5億美元

视频滚动新闻

禮來：小分子GLP-1啓動壓力性尿失禁三期臨牀

輝瑞收購「Metsera」超長效GLP-1減重新藥「MET-097i」II期臨牀數據亮眼

輝瑞(PFE.US)超長效GLP-1兩項減重II期研究取得積極結果

即將被輝瑞收購的Metsera公佈GLP-1候選藥物兩項II期試驗積極結果

開源證券：小核酸藥物有望成為減重賽道新風口聯用GLP-1或多重滿足臨牀需求

諾和諾德、禮來強勢領跑，恆瑞、信達如何突圍GLP-1紅海？

諾和諾德全球首款口服GLP-1減重藥療效數據刷新紀錄

美通社头条

警惕GLP-1「陷阱」

攪局GLP-1減肥藥，輝瑞砸超70億美元買下一家上市公司，諾和諾德、禮來又有新對手

港股異動 | 派格生物醫藥-B(02565)午前漲超5% GLP-1多靶點領域臨牀進度靠前 PB-718為公司旗下重磅品種

諾和諾德：GLP-1/GIP/Amylin三靶點激動劑啓動二期臨牀

信達生物：減肥藥瑪仕度肽獲批糖尿病適應症為全球首個GCG/GLP-1雙受體激動降糖藥

中國生物製藥(01177)：TQF3250膠囊「GLP-1受體激動劑」臨牀試驗申請獲NMPA受理

繼 GLP-1 之後，小核酸接棒，有望開啓千億減重賽道「第二增長曲線」

信達生物：瑪仕度肽獲批2型糖尿病治療許可，GLP-1類藥物開啓適應症擴容競爭

红星资本局

減重藥巨頭在口服藥上拼數據：禮來宣佈自研GLP-1製劑降糖、減重效果優於口服司美格魯肽

每日经济新闻

Grvt 完成 1900 萬美元 A 輪孖展，投資方包括 ZKsync、Further Ventures、EigenCloud 等，引領隱私優先的鏈上金融，開啓萬億美元市場新篇章

GLP-1藥物使用或推動能量飲料銷售增長

禮來小分子GLP-1：減重不及預期，降糖為何擊敗司美格魯肽

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/GLP/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GLP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GLP\",,,,,undefined,":{"symbol":"GLP","market":"US","secType":"STK","nameCN":"Global Partners Lp","latestPrice":43.905,"timestamp":1760642683121,"preClose":44.95,"halted":0,"volume":29405,"delay":0,"floatShares":27674174,"shares":33995563,"eps":2.600398,"marketStatus":"交易中","change":-1.045,"latestTime":"10-16 15:24:52 EDT","open":45.15,"high":45.15,"low":43.8575,"amount":1302940.2548,"amplitude":0.028754,"askPrice":44.11,"askSize":38,"bidPrice":43.74,"bidSize":12,"shortable":3,"etf":0,"ttmEps":2.600398,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1760644800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1127966400000,"exchange":"NYSE","adjPreClose":44.95,"dividendRate":0.067646,"preHourTrading":{"tag":"盘前","latestPrice":45.64,"preClose":44.95,"latestTime":"08:00 EDT","volume":12,"amount":547.6800000000001,"timestamp":1760616003023},"postHourTrading":{"tag":"盘后","latestPrice":44.95,"preClose":44.95,"latestTime":"16:10 EDT","volume":1888,"amount":84865.6,"timestamp":1760559004489},"volumeRatio":0.525873,"impliedVol":0.1874,"impliedVolPercentile":0.104},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GLP\",,,,,undefined,":{"symbol":"GLP","floatShares":27674174,"roa":"4.09%","roe":"16.33%","lyrEps":2.44604,"volumeRatio":0.525873,"shares":33995563,"dividePrice":2.97,"high":45.15,"amplitude":0.028754,"preClose":44.95,"low":43.8575,"week52Low":43.2,"pbRate":"2.44","psRate":"0.08","week52High":60,"institutionHeld":0.4647,"latestPrice":43.905,"committee":-0.52,"eps":2.600398,"divideRate":0.067646,"volume":29405,"delay":0,"ttmEps":2.600398,"open":45.15,"prevYearClose":46.55,"prevWeekClose":43.87,"prevMonthClose":48,"prevQuarterClose":48,"fiveDayClose":44.51,"twentyDayClose":50.85,"sixtyDayClose":51.94},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GLP\",params:#limit:5,,,undefined,":[{"date":"2025-08-08","symbol":"GLP","amount":0.75,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-08-08","defaultRemindTime":1754659800000,"name":"Global Partners Lp","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-08-14","payableDate":"2025-08-08","currency":"USD","dateTimestamp":1754625600000,"payDate":"2025-08-14"},{"market":"US","date":"2025-08-07","symbol":"GLP","fiscalQuarterEnding":"2025/06","expectedEps":0.6,"name":null,"time":"盤前","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"pre","actualEps":0.55},{"date":"2025-05-09","symbol":"GLP","amount":0.745,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-09","defaultRemindTime":1746797400000,"name":"Global Partners Lp","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-15","payableDate":"2025-05-09","currency":"USD","dateTimestamp":1746763200000,"payDate":"2025-05-15"},{"market":"US","date":"2025-05-08","symbol":"GLP","fiscalQuarterEnding":"2025/03","expectedEps":-0.03,"name":null,"time":"盤前","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"pre","actualEps":0.36},{"market":"US","date":"2025-02-28","symbol":"GLP","fiscalQuarterEnding":"2024/12","expectedEps":0.24,"name":null,"time":"盤前","type":"earning","dateTimestamp":1740718800000,"reportTimeType":"pre","actualEps":0.52}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GLP\",market:\"US\",,,undefined,":[{"executeDate":"2015-11-02","recordDate":"2015-11-04","paymentDate":"2015-11-13","value":0.6975,"currency":"USD"},{"executeDate":"2016-02-08","recordDate":"2016-02-10","paymentDate":"2016-02-16","value":0.4625,"currency":"USD"},{"executeDate":"2016-05-04","recordDate":"2016-05-06","paymentDate":"2016-05-16","value":0.4625,"currency":"USD"},{"executeDate":"2016-08-04","recordDate":"2016-08-08","paymentDate":"2016-08-12","value":0.4625,"currency":"USD"},{"executeDate":"2016-11-04","recordDate":"2016-11-08","paymentDate":"2016-11-14","value":0.4625,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GLP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":2,"updateTime":1741060800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GLP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GLP","date":"2025-10-15","current":16.883954,"percent":0.771268,"low":2.771386,"twenty":4.440923,"median":10.625534,"eighty":16.329708,"high":29.34912,"avg":11.246133,"sd":6.361508,"marketCap":1517070421},"quantilePoints":[{"date":"2020-10-16","current":5.26448,"twenty":6.239772,"median":7.932539,"eighty":11.247278,"marketCap":487217087},{"date":"2020-10-23","current":5.271843,"twenty":6.23717,"median":7.912422,"eighty":11.243223,"marketCap":487898510},{"date":"2020-10-30","current":5.338109,"twenty":6.227089,"median":7.896854,"eighty":11.239367,"marketCap":494031312},{"date":"2020-11-06","current":5.459545,"twenty":6.22179,"median":7.88907,"eighty":11.21862,"marketCap":522855188},{"date":"2020-11-13","current":5.670214,"twenty":6.203808,"median":7.87934,"eighty":11.19873,"marketCap":543030764},{"date":"2020-11-20","current":5.877313,"twenty":6.196135,"median":7.85015,"eighty":11.194013,"marketCap":562864382},{"date":"2020-11-27","current":6.170107,"twenty":6.185826,"median":7.85015,"eighty":11.189536,"marketCap":590905013},{"date":"2020-12-04","current":6.109406,"twenty":6.168749,"median":7.838474,"eighty":11.169685,"marketCap":585091712},{"date":"2020-12-11","current":6.416483,"twenty":6.167844,"median":7.834582,"eighty":11.145422,"marketCap":614500179},{"date":"2020-12-18","current":6.230809,"twenty":6.167844,"median":7.828744,"eighty":11.130907,"marketCap":596718315},{"date":"2020-12-24","current":6.048705,"twenty":6.167844,"median":7.82096,"eighty":11.115597,"marketCap":579278410},{"date":"2020-12-31","current":5.934444,"twenty":6.167844,"median":7.817068,"eighty":11.101741,"marketCap":568335725},{"date":"2021-01-08","current":6.062987,"twenty":6.149862,"median":7.795662,"eighty":11.084422,"marketCap":580646246},{"date":"2021-01-15","current":6.216526,"twenty":6.149862,"median":7.785585,"eighty":11.084422,"marketCap":595350479},{"date":"2021-01-22","current":6.705707,"twenty":6.149862,"median":7.780094,"eighty":11.074992,"marketCap":642198851},{"date":"2021-01-29","current":7.180605,"twenty":6.149862,"median":7.776202,"eighty":11.068208,"marketCap":687679388},{"date":"2021-02-05","current":7.284155,"twenty":6.149862,"median":7.768418,"eighty":11.06411,"marketCap":697596196},{"date":"2021-02-12","current":6.934229,"twenty":6.163202,"median":7.760634,"eighty":11.053134,"marketCap":664084222},{"date":"2021-02-19","current":7.112763,"twenty":6.167321,"median":7.75285,"eighty":11.04396,"marketCap":681182168},{"date":"2021-02-26","current":7.202029,"twenty":6.167844,"median":7.741174,"eighty":11.038761,"marketCap":689731141},{"date":"2021-03-05","current":6.896217,"twenty":6.167844,"median":7.718575,"eighty":11.032407,"marketCap":695214499},{"date":"2021-03-12","current":7.842623,"twenty":6.167844,"median":7.698362,"eighty":11.017031,"marketCap":790622686},{"date":"2021-03-19","current":7.720506,"twenty":6.167844,"median":7.718575,"eighty":11.007626,"marketCap":778311953},{"date":"2021-03-26","current":7.411822,"twenty":6.167844,"median":7.69367,"eighty":11.00501,"marketCap":747193153},{"date":"2021-04-01","current":7.320234,"twenty":6.167844,"median":7.686686,"eighty":10.988222,"marketCap":737960103},{"date":"2021-04-09","current":7.3779,"twenty":6.167844,"median":7.67501,"eighty":10.954813,"marketCap":743773505},{"date":"2021-04-16","current":7.510194,"twenty":6.168749,"median":7.659442,"eighty":10.940212,"marketCap":757110133},{"date":"2021-04-23","current":7.364332,"twenty":6.170107,"median":7.594997,"eighty":10.930856,"marketCap":742405645},{"date":"2021-04-30","current":8.185229,"twenty":6.171613,"median":7.641929,"eighty":10.912383,"marketCap":825161134},{"date":"2021-05-07","current":9.181725,"twenty":6.178654,"median":7.67501,"eighty":10.905455,"marketCap":849502414},{"date":"2021-05-14","current":8.749253,"twenty":6.185826,"median":7.686686,"eighty":10.905455,"marketCap":809489619},{"date":"2021-05-21","current":9.203903,"twenty":6.185826,"median":7.690578,"eighty":10.897433,"marketCap":851554353},{"date":"2021-05-28","current":9.407203,"twenty":6.185826,"median":7.712361,"eighty":10.877257,"marketCap":870363786},{"date":"2021-06-04","current":9.706607,"twenty":6.189262,"median":7.720506,"eighty":10.864653,"marketCap":898064952},{"date":"2021-06-11","current":10.061456,"twenty":6.203126,"median":7.741174,"eighty":10.858681,"marketCap":930895963},{"date":"2021-06-18","current":9.603109,"twenty":6.203644,"median":7.748958,"eighty":10.836624,"marketCap":888489240},{"date":"2021-06-25","current":9.680732,"twenty":6.203808,"median":7.760634,"eighty":10.817799,"marketCap":895671024},{"date":"2021-07-02","current":9.658554,"twenty":6.203808,"median":7.768418,"eighty":10.809851,"marketCap":893619086},{"date":"2021-07-09","current":9.31849,"twenty":6.203808,"median":7.778148,"eighty":10.796921,"marketCap":862156033},{"date":"2021-07-16","current":8.963641,"twenty":6.213362,"median":7.780094,"eighty":10.785892,"marketCap":829325022},{"date":"2021-07-23","current":9.495915,"twenty":6.213362,"median":7.785616,"eighty":10.763835,"marketCap":878571539},{"date":"2021-07-30","current":9.909906,"twenty":6.216526,"median":7.795662,"eighty":10.752807,"marketCap":916874385},{"date":"2021-08-06","current":29.34912,"twenty":6.22179,"median":7.817068,"eighty":10.752807,"marketCap":823536295},{"date":"2021-08-13","current":26.023372,"twenty":6.22179,"median":7.822906,"eighty":10.813084,"marketCap":730215805},{"date":"2021-08-20","current":24.554702,"twenty":6.22179,"median":7.83069,"eighty":10.865043,"marketCap":689004931},{"date":"2021-08-27","current":24.530426,"twenty":6.22179,"median":7.834582,"eighty":10.905455,"marketCap":688323760},{"date":"2021-09-03","current":25.100901,"twenty":6.22179,"median":7.842494,"eighty":10.964493,"marketCap":704331289},{"date":"2021-09-10","current":24.275533,"twenty":6.228856,"median":7.848204,"eighty":11.013201,"marketCap":681171460},{"date":"2021-09-17","current":25.198003,"twenty":6.230622,"median":7.85015,"eighty":11.053134,"marketCap":707055975},{"date":"2021-09-24","current":24.894559,"twenty":6.230772,"median":7.876969,"eighty":11.084422,"marketCap":698541332},{"date":"2021-10-01","current":26.047647,"twenty":6.233421,"median":7.883329,"eighty":11.141011,"marketCap":730896976},{"date":"2021-10-08","current":26.897291,"twenty":6.234318,"median":7.892962,"eighty":11.19642,"marketCap":754737977},{"date":"2021-10-15","current":26.836602,"twenty":6.236185,"median":7.896854,"eighty":11.246674,"marketCap":753035049},{"date":"2021-10-22","current":28.632991,"twenty":6.237348,"median":7.914368,"eighty":11.269162,"marketCap":803441737},{"date":"2021-10-29","current":28.329547,"twenty":6.237865,"median":7.935774,"eighty":11.303569,"marketCap":794927093},{"date":"2021-11-05","current":18.151279,"twenty":6.239408,"median":7.94745,"eighty":11.328048,"marketCap":776838422},{"date":"2021-11-12","current":18.191189,"twenty":6.239772,"median":7.988112,"eighty":11.346522,"marketCap":778546510},{"date":"2021-11-19","current":18.773882,"twenty":6.239772,"median":8.014118,"eighty":11.360961,"marketCap":803484595},{"date":"2021-11-26","current":18.694061,"twenty":6.239772,"median":8.035981,"eighty":11.378852,"marketCap":800068419},{"date":"2021-12-03","current":18.103386,"twenty":6.239772,"median":8.105729,"eighty":11.403489,"marketCap":774788716},{"date":"2021-12-10","current":18.430652,"twenty":6.240495,"median":8.179783,"eighty":11.427136,"marketCap":788795038},{"date":"2021-12-17","current":18.550383,"twenty":6.243048,"median":8.213544,"eighty":11.470285,"marketCap":793919302},{"date":"2021-12-23","current":17.991637,"twenty":6.244429,"median":8.252749,"eighty":11.474686,"marketCap":770006070},{"date":"2021-12-31","current":18.749936,"twenty":6.244429,"median":8.284603,"eighty":11.575574,"marketCap":802459742},{"date":"2022-01-07","current":20.051017,"twenty":6.24581,"median":8.291955,"eighty":11.616705,"marketCap":858143411},{"date":"2022-01-14","current":21.152545,"twenty":6.248234,"median":8.320498,"eighty":11.690231,"marketCap":905286640},{"date":"2022-01-21","current":20.146802,"twenty":6.249277,"median":8.363015,"eighty":11.729858,"marketCap":862242822},{"date":"2022-01-28","current":21.392008,"twenty":6.251718,"median":8.365465,"eighty":11.776801,"marketCap":915535168},{"date":"2022-02-04","current":21.85497,"twenty":6.254157,"median":8.433466,"eighty":11.837284,"marketCap":935348988},{"date":"2022-02-11","current":21.559632,"twenty":6.257754,"median":8.47328,"eighty":11.938846,"marketCap":922709137},{"date":"2022-02-18","current":20.945011,"twenty":6.257851,"median":8.48054,"eighty":12.432666,"marketCap":896404582},{"date":"2022-02-25","current":20.529942,"twenty":6.258237,"median":8.487891,"eighty":12.775373,"marketCap":878640467},{"date":"2022-03-04","current":15.348683,"twenty":6.268592,"median":8.571294,"eighty":13.121553,"marketCap":878174885},{"date":"2022-03-11","current":15.504022,"twenty":6.275496,"median":8.601399,"eighty":13.154839,"marketCap":887062603},{"date":"2022-03-18","current":15.940166,"twenty":6.275736,"median":8.649704,"eighty":13.201441,"marketCap":912016580},{"date":"2022-03-25","current":16.890123,"twenty":6.275736,"median":8.669307,"eighty":13.248042,"marketCap":966368393},{"date":"2022-04-01","current":16.214996,"twenty":6.275736,"median":8.68891,"eighty":13.261356,"marketCap":927741004},{"date":"2022-04-08","current":16.752708,"twenty":6.275736,"median":8.726599,"eighty":13.281328,"marketCap":958506181},{"date":"2022-04-14","current":16.573471,"twenty":6.275736,"median":8.736337,"eighty":13.3013,"marketCap":948251122},{"date":"2022-04-22","current":16.011861,"twenty":6.276168,"median":8.777122,"eighty":13.329261,"marketCap":916118604},{"date":"2022-04-29","current":15.743005,"twenty":6.281175,"median":8.797306,"eighty":13.342575,"marketCap":900736015},{"date":"2022-05-06","current":9.804164,"twenty":6.2824,"median":8.848712,"eighty":13.349233,"marketCap":897659497},{"date":"2022-05-13","current":9.69216,"twenty":6.2824,"median":8.9103,"eighty":13.347901,"marketCap":887404438},{"date":"2022-05-20","current":10.270852,"twenty":6.291454,"median":8.930374,"eighty":13.347901,"marketCap":940388910},{"date":"2022-05-27","current":11.163158,"twenty":6.293718,"median":8.972794,"eighty":13.342575,"marketCap":1022087547},{"date":"2022-06-03","current":10.868211,"twenty":6.294536,"median":8.995202,"eighty":13.341244,"marketCap":995082558},{"date":"2022-06-10","current":10.244717,"twenty":6.297672,"median":9.026396,"eighty":13.341244,"marketCap":937996063},{"date":"2022-06-17","current":7.754474,"twenty":6.299555,"median":9.016925,"eighty":13.33725,"marketCap":709991918},{"date":"2022-06-24","current":8.613179,"twenty":6.299659,"median":8.99034,"eighty":13.331924,"marketCap":788614037},{"date":"2022-07-01","current":8.814788,"twenty":6.299659,"median":8.977241,"eighty":13.322603,"marketCap":807073143},{"date":"2022-07-08","current":8.900658,"twenty":6.299659,"median":8.963641,"eighty":13.313284,"marketCap":814935355},{"date":"2022-07-15","current":8.867057,"twenty":6.299659,"median":8.92485,"eighty":13.306626,"marketCap":811858837},{"date":"2022-07-22","current":9.561487,"twenty":6.300172,"median":8.963641,"eighty":13.3013,"marketCap":875440203},{"date":"2022-07-29","current":10.371656,"twenty":6.303369,"median":8.980096,"eighty":13.299969,"marketCap":949618463},{"date":"2022-08-05","current":3.850073,"twenty":6.303369,"median":8.997729,"eighty":13.29198,"marketCap":927520968},{"date":"2022-08-12","current":4.016293,"twenty":6.299659,"median":8.972794,"eighty":13.281328,"marketCap":967565231},{"date":"2022-08-19","current":3.999245,"twenty":6.293991,"median":8.937993,"eighty":13.278687,"marketCap":963458127},{"date":"2022-08-26","current":3.899797,"twenty":6.2824,"median":8.919306,"eighty":13.268103,"marketCap":939500021},{"date":"2022-09-02","current":4.077383,"twenty":6.275736,"median":8.9103,"eighty":13.268014,"marketCap":982282354},{"date":"2022-09-09","current":4.169728,"twenty":6.275496,"median":8.900658,"eighty":13.268014,"marketCap":1004529167},{"date":"2022-09-16","current":4.014873,"twenty":6.257754,"median":8.857885,"eighty":13.261356,"marketCap":967222973},{"date":"2022-09-23","current":3.607134,"twenty":6.247881,"median":8.814788,"eighty":13.254699,"marketCap":868994737},{"date":"2022-09-30","current":3.51621,"twenty":6.240977,"median":8.791187,"eighty":13.254699,"marketCap":847090183},{"date":"2022-10-07","current":3.916845,"twenty":6.239772,"median":8.777122,"eighty":13.248042,"marketCap":943607125},{"date":"2022-10-14","current":3.740679,"twenty":6.236636,"median":8.755886,"eighty":13.248042,"marketCap":901167051},{"date":"2022-10-21","current":4.087328,"twenty":6.230622,"median":8.734756,"eighty":13.241384,"marketCap":984678164},{"date":"2022-10-28","current":4.250707,"twenty":6.22179,"median":8.716798,"eighty":13.234727,"marketCap":1024037910},{"date":"2022-11-04","current":3.449288,"twenty":6.213362,"median":8.68891,"eighty":13.208098,"marketCap":1095762902},{"date":"2022-11-11","current":3.301892,"twenty":6.203808,"median":8.669307,"eighty":13.201441,"marketCap":1048938349},{"date":"2022-11-18","current":3.311575,"twenty":6.185826,"median":8.649704,"eighty":13.194783,"marketCap":1052014414},{"date":"2022-11-25","current":3.399797,"twenty":6.17312,"median":8.639313,"eighty":13.17348,"marketCap":1080040789},{"date":"2022-12-02","current":3.385811,"twenty":6.167844,"median":8.62969,"eighty":13.162828,"marketCap":1075597583},{"date":"2022-12-09","current":3.518145,"twenty":6.167844,"median":8.601399,"eighty":13.156171,"marketCap":1117637146},{"date":"2022-12-16","current":3.574091,"twenty":6.149862,"median":8.577106,"eighty":13.154839,"marketCap":1135409969},{"date":"2022-12-23","current":3.865656,"twenty":6.146266,"median":8.549709,"eighty":13.144188,"marketCap":1228033720},{"date":"2022-12-30","current":3.740853,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1188386653},{"date":"2023-01-06","current":3.441757,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1093370406},{"date":"2023-01-13","current":3.612823,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1147714231},{"date":"2023-01-20","current":3.620354,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1150106726},{"date":"2023-01-27","current":3.857048,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1225299440},{"date":"2023-02-03","current":4.130323,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1312112845},{"date":"2023-02-10","current":3.93774,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1250933319},{"date":"2023-02-17","current":3.875339,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1231109786},{"date":"2023-02-24","current":3.718259,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1181209167},{"date":"2023-03-03","current":3.363192,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1194165378},{"date":"2023-03-10","current":3.211151,"twenty":6.113691,"median":8.482899,"eighty":13.133536,"marketCap":1140180220},{"date":"2023-03-17","current":2.830086,"twenty":6.097582,"median":8.463126,"eighty":13.133536,"marketCap":1004875645},{"date":"2023-03-24","current":2.875313,"twenty":6.070129,"median":8.365465,"eighty":13.133536,"marketCap":1020934521},{"date":"2023-03-31","current":2.985014,"twenty":6.034422,"median":8.291955,"eighty":13.130873,"marketCap":1059885838},{"date":"2023-04-06","current":2.892634,"twenty":6.016569,"median":8.274802,"eighty":13.130873,"marketCap":1027084729},{"date":"2023-04-14","current":2.896483,"twenty":5.960153,"median":8.185229,"eighty":13.133536,"marketCap":1028451442},{"date":"2023-04-20","current":2.925352,"twenty":5.879004,"median":8.105729,"eighty":13.133536,"marketCap":1038701788},{"date":"2023-04-28","current":2.932088,"twenty":5.726233,"median":7.998046,"eighty":13.136199,"marketCap":1041093536},{"date":"2023-05-05","current":2.771386,"twenty":5.536171,"median":7.943558,"eighty":13.136199,"marketCap":984033273},{"date":"2023-05-12","current":2.975648,"twenty":5.442294,"median":7.932539,"eighty":13.136199,"marketCap":1050433502},{"date":"2023-05-19","current":3.089052,"twenty":5.341054,"median":7.932539,"eighty":13.136199,"marketCap":1090466310},{"date":"2023-05-26","current":2.874844,"twenty":5.253436,"median":7.932539,"eighty":13.136199,"marketCap":1014848784},{"date":"2023-06-02","current":2.846736,"twenty":5.130475,"median":7.932539,"eighty":13.136199,"marketCap":1004926122},{"date":"2023-06-09","current":3.07839,"twenty":5.004569,"median":7.932539,"eighty":13.136199,"marketCap":1086702542},{"date":"2023-06-16","current":3.058036,"twenty":4.918423,"median":7.932539,"eighty":13.136199,"marketCap":1079517166},{"date":"2023-06-23","current":2.916523,"twenty":4.864674,"median":7.935774,"eighty":13.138862,"marketCap":1029561696},{"date":"2023-06-30","current":2.952386,"twenty":4.815342,"median":7.93772,"eighty":13.141525,"marketCap":1042221644},{"date":"2023-07-07","current":2.944631,"twenty":4.771165,"median":7.93772,"eighty":13.141525,"marketCap":1039484358},{"date":"2023-07-14","current":3.066759,"twenty":4.749076,"median":7.93772,"eighty":13.141525,"marketCap":1082596613},{"date":"2023-07-21","current":3.116192,"twenty":4.697536,"median":7.93772,"eighty":13.141525,"marketCap":1100046811},{"date":"2023-07-28","current":3.215057,"twenty":4.671766,"median":7.93772,"eighty":13.141525,"marketCap":1134947207},{"date":"2023-08-04","current":3.279998,"twenty":4.616544,"median":7.93772,"eighty":13.141525,"marketCap":1157871978},{"date":"2023-08-11","current":4.645552,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1075069076},{"date":"2023-08-18","current":4.647031,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1075411237},{"date":"2023-08-25","current":4.663295,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1079175005},{"date":"2023-09-01","current":4.624853,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1070278826},{"date":"2023-09-08","current":4.647031,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1075411237},{"date":"2023-09-15","current":4.775663,"twenty":4.570147,"median":7.93772,"eighty":13.141525,"marketCap":1105179222},{"date":"2023-09-22","current":4.867332,"twenty":4.570147,"median":7.93772,"eighty":13.141525,"marketCap":1126393189},{"date":"2023-09-29","current":5.173389,"twenty":4.570147,"median":7.93772,"eighty":13.141525,"marketCap":1197220464},{"date":"2023-10-06","current":4.475521,"twenty":4.542915,"median":7.93772,"eighty":13.141525,"marketCap":1035720590},{"date":"2023-10-13","current":4.511006,"twenty":4.484012,"median":7.93772,"eighty":13.141525,"marketCap":1043932448},{"date":"2023-10-20","current":4.482914,"twenty":4.482914,"median":7.93772,"eighty":13.141525,"marketCap":1037431394},{"date":"2023-10-27","current":4.534662,"twenty":4.467537,"median":7.94745,"eighty":13.149513,"marketCap":1049407020},{"date":"2023-11-03","current":4.904296,"twenty":4.458666,"median":7.94745,"eighty":13.149513,"marketCap":1134947207},{"date":"2023-11-10","current":7.439549,"twenty":4.458666,"median":7.935774,"eighty":13.149513,"marketCap":1088071185},{"date":"2023-11-17","current":7.820894,"twenty":4.458666,"median":7.896854,"eighty":13.149513,"marketCap":1143844827},{"date":"2023-11-24","current":7.993518,"twenty":4.458666,"median":7.896854,"eighty":13.149513,"marketCap":1169092039},{"date":"2023-12-01","current":8.460278,"twenty":4.458666,"median":7.896854,"eighty":13.149513,"marketCap":1237357955},{"date":"2023-12-08","current":8.743603,"twenty":4.459848,"median":7.902692,"eighty":13.146851,"marketCap":1278795691},{"date":"2023-12-15","current":8.690189,"twenty":4.459848,"median":7.902692,"eighty":13.146851,"marketCap":1270983658},{"date":"2023-12-22","current":9.616802,"twenty":4.459848,"median":7.934448,"eighty":13.146851,"marketCap":1406505433},{"date":"2023-12-29","current":9.686473,"twenty":4.4563,"median":7.940074,"eighty":13.154839,"marketCap":1416695040},{"date":"2024-01-05","current":9.75382,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1426544994},{"date":"2024-01-12","current":9.809556,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1434696679},{"date":"2024-01-19","current":10.16023,"twenty":4.448612,"median":7.939666,"eighty":13.154839,"marketCap":1485984368},{"date":"2024-01-26","current":10.740814,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1570897761},{"date":"2024-02-02","current":10.601474,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1550518547},{"date":"2024-02-09","current":10.963759,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1603504503},{"date":"2024-02-16","current":11.124,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1626940600},{"date":"2024-02-23","current":10.647921,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1557311618},{"date":"2024-03-01","current":11.10678,"twenty":4.4563,"median":7.940074,"eighty":13.154839,"marketCap":1583804596},{"date":"2024-03-08","current":11.32675,"twenty":4.4563,"median":7.94745,"eighty":13.154839,"marketCap":1615171958},{"date":"2024-03-15","current":10.799262,"twenty":4.4563,"median":7.990262,"eighty":13.154839,"marketCap":1539953125},{"date":"2024-03-22","current":11.659401,"twenty":4.4563,"median":8.049544,"eighty":13.154839,"marketCap":1662607257},{"date":"2024-03-28","current":10.571159,"twenty":4.4563,"median":8.239503,"eighty":13.154839,"marketCap":1507426062},{"date":"2024-04-05","current":10.811142,"twenty":4.452456,"median":8.461702,"eighty":13.154839,"marketCap":1541647243},{"date":"2024-04-12","current":11.186562,"twenty":4.452456,"median":8.566313,"eighty":13.154839,"marketCap":1595181367},{"date":"2024-04-19","current":10.81827,"twenty":4.452456,"median":8.624771,"eighty":13.154839,"marketCap":1542663714},{"date":"2024-04-26","current":11.245964,"twenty":4.4563,"median":8.639313,"eighty":13.154839,"marketCap":1603651956},{"date":"2024-05-03","current":11.324374,"twenty":4.4563,"median":8.690189,"eighty":13.154839,"marketCap":1614833134},{"date":"2024-05-10","current":14.682959,"twenty":4.4563,"median":8.734756,"eighty":13.168154,"marketCap":1565364893},{"date":"2024-05-17","current":13.78037,"twenty":4.4563,"median":8.734756,"eighty":13.224197,"marketCap":1469138999},{"date":"2024-05-24","current":14.166489,"twenty":4.4563,"median":8.734756,"eighty":13.241384,"marketCap":1510303519},{"date":"2024-05-31","current":15.403069,"twenty":4.4563,"median":8.734756,"eighty":13.248042,"marketCap":1642136538},{"date":"2024-06-07","current":15.399881,"twenty":4.4563,"median":8.734756,"eighty":13.254699,"marketCap":1641796762},{"date":"2024-06-14","current":15.042931,"twenty":4.4563,"median":8.734756,"eighty":13.254699,"marketCap":1603741870},{"date":"2024-06-21","current":14.389583,"twenty":4.452456,"median":8.72747,"eighty":13.257384,"marketCap":1534087827},{"date":"2024-06-28","current":14.542562,"twenty":4.452456,"median":8.72747,"eighty":13.270766,"marketCap":1550397066},{"date":"2024-07-05","current":14.395957,"twenty":4.452456,"median":8.72747,"eighty":13.285322,"marketCap":1534767378},{"date":"2024-07-12","current":13.586443,"twenty":4.452456,"median":8.72747,"eighty":13.285322,"marketCap":1448464320},{"date":"2024-07-19","current":12.767369,"twenty":4.452456,"median":8.72747,"eighty":13.228966,"marketCap":1361141934},{"date":"2024-07-26","current":12.910786,"twenty":4.452456,"median":8.72747,"eighty":13.052045,"marketCap":1376431846},{"date":"2024-08-02","current":13.302795,"twenty":4.452456,"median":8.72747,"eighty":12.924809,"marketCap":1418224272},{"date":"2024-08-09","current":12.449802,"twenty":4.452456,"median":8.72747,"eighty":12.75462,"marketCap":1335540014},{"date":"2024-08-16","current":13.196601,"twenty":4.452456,"median":8.72747,"eighty":12.789678,"marketCap":1415652134},{"date":"2024-08-23","current":13.473893,"twenty":4.452456,"median":8.72747,"eighty":13.02799,"marketCap":1445398406},{"date":"2024-08-30","current":14.204937,"twenty":4.452456,"median":8.72747,"eighty":13.191559,"marketCap":1523820396},{"date":"2024-09-06","current":13.316341,"twenty":4.452456,"median":8.72747,"eighty":13.222287,"marketCap":1428497115},{"date":"2024-09-13","current":13.558971,"twenty":4.452456,"median":8.72747,"eighty":13.305504,"marketCap":1454525103},{"date":"2024-09-20","current":14.226994,"twenty":4.452456,"median":8.72747,"eighty":13.395117,"marketCap":1526186577},{"date":"2024-09-27","current":14.085197,"twenty":4.452456,"median":8.72747,"eighty":13.544476,"marketCap":1510975415},{"date":"2024-10-04","current":14.976944,"twenty":4.452456,"median":8.72747,"eighty":13.679972,"marketCap":1606636722},{"date":"2024-10-11","current":14.803637,"twenty":4.452456,"median":8.72747,"eighty":13.85562,"marketCap":1588045302},{"date":"2024-10-18","current":14.529495,"twenty":4.452456,"median":8.72747,"eighty":14.019655,"marketCap":1558637056},{"date":"2024-10-25","current":14.772126,"twenty":4.452456,"median":8.72747,"eighty":14.168401,"marketCap":1584665044},{"date":"2024-11-01","current":14.778428,"twenty":4.452456,"median":8.72747,"eighty":14.27768,"marketCap":1585341095},{"date":"2024-11-08","current":13.141823,"twenty":4.452456,"median":8.73918,"eighty":14.377354,"marketCap":1640493731},{"date":"2024-11-15","current":13.379586,"twenty":4.452456,"median":8.78252,"eighty":14.377354,"marketCap":1670173717},{"date":"2024-11-22","current":14.322533,"twenty":4.452456,"median":8.81344,"eighty":14.377354,"marketCap":1787881840},{"date":"2024-11-29","current":15.251971,"twenty":4.452456,"median":8.883858,"eighty":14.399781,"marketCap":1903903601},{"date":"2024-12-06","current":15.273586,"twenty":4.452456,"median":8.934183,"eighty":14.482822,"marketCap":1906601781},{"date":"2024-12-13","current":14.4198,"twenty":4.452456,"median":9.012663,"eighty":14.537463,"marketCap":1800023652},{"date":"2024-12-20","current":12.93378,"twenty":4.452456,"median":9.090449,"eighty":14.537463,"marketCap":1614523744},{"date":"2024-12-27","current":12.995923,"twenty":4.452456,"median":9.19602,"eighty":14.537463,"marketCap":1622281013},{"date":"2025-01-03","current":12.766265,"twenty":4.452456,"median":9.268408,"eighty":14.537463,"marketCap":1593612846},{"date":"2025-01-10","current":12.631172,"twenty":4.448612,"median":9.31881,"eighty":14.538738,"marketCap":1576749218},{"date":"2025-01-17","current":14.282006,"twenty":4.448612,"median":9.382279,"eighty":14.538738,"marketCap":1782822752},{"date":"2025-01-24","current":13.892938,"twenty":4.448612,"median":9.455255,"eighty":14.538738,"marketCap":1734255503},{"date":"2025-01-31","current":14.63865,"twenty":4.448612,"median":9.481129,"eighty":14.558635,"marketCap":1827342730},{"date":"2025-02-07","current":15.684268,"twenty":4.448612,"median":9.514397,"eighty":14.63454,"marketCap":1957867210},{"date":"2025-02-14","current":15.462716,"twenty":4.448612,"median":9.568033,"eighty":14.675959,"marketCap":1930210860},{"date":"2025-02-21","current":15.732902,"twenty":4.448612,"median":9.580931,"eighty":14.694621,"marketCap":1963938116},{"date":"2025-02-28","current":20.937616,"twenty":4.448612,"median":9.626092,"eighty":14.774647,"marketCap":1933567942},{"date":"2025-03-07","current":19.49754,"twenty":4.444767,"median":9.675026,"eighty":14.838928,"marketCap":1800578330},{"date":"2025-03-14","current":19.960552,"twenty":4.444767,"median":9.675026,"eighty":14.901539,"marketCap":1843337016},{"date":"2025-03-21","current":19.362647,"twenty":4.444767,"median":9.689317,"eighty":15.017908,"marketCap":1788121076},{"date":"2025-03-28","current":19.698057,"twenty":4.444767,"median":9.708699,"eighty":15.110765,"marketCap":1819095871},{"date":"2025-04-04","current":17.87153,"twenty":4.444767,"median":9.75606,"eighty":15.125044,"marketCap":1650417909},{"date":"2025-04-11","current":17.576223,"twenty":4.448612,"median":9.799015,"eighty":15.243459,"marketCap":1623146621},{"date":"2025-04-17","current":18.509538,"twenty":4.448612,"median":9.802712,"eighty":15.283315,"marketCap":1709337357},{"date":"2025-04-25","current":18.910572,"twenty":4.444767,"median":9.80686,"eighty":15.360398,"marketCap":1746372438},{"date":"2025-05-02","current":18.710055,"twenty":4.444767,"median":9.80686,"eighty":15.401794,"marketCap":1727854897},{"date":"2025-05-09","current":14.05872,"twenty":4.444767,"median":9.80686,"eighty":15.43196,"marketCap":1621799891},{"date":"2025-05-16","current":14.406029,"twenty":4.444767,"median":9.80686,"eighty":15.43196,"marketCap":1661865116},{"date":"2025-05-23","current":14.373925,"twenty":4.444767,"median":9.80686,"eighty":15.43196,"marketCap":1658161608},{"date":"2025-05-30","current":15.450609,"twenty":4.444767,"median":9.80686,"eighty":15.444645,"marketCap":1782366767},{"date":"2025-06-06","current":15.621074,"twenty":4.444767,"median":9.80686,"eighty":15.514776,"marketCap":1802031456},{"date":"2025-06-13","current":16.520424,"twenty":4.444767,"median":9.80686,"eighty":15.572999,"marketCap":1905779645},{"date":"2025-06-20","current":16.170677,"twenty":4.440923,"median":9.804164,"eighty":15.627805,"marketCap":1865433127},{"date":"2025-06-27","current":15.57111,"twenty":4.440923,"median":9.804164,"eighty":15.665123,"marketCap":1796267668},{"date":"2025-07-03","current":15.479999,"twenty":4.440923,"median":9.804164,"eighty":15.665123,"marketCap":1785757230},{"date":"2025-07-11","current":15.432974,"twenty":4.440923,"median":9.804164,"eighty":15.665123,"marketCap":1780332488},{"date":"2025-07-18","current":14.992116,"twenty":4.440923,"median":9.804164,"eighty":15.665123,"marketCap":1729475533},{"date":"2025-07-25","current":15.333047,"twenty":4.440923,"median":9.804164,"eighty":15.665123,"marketCap":1768804912},{"date":"2025-08-01","current":15.430035,"twenty":4.440923,"median":9.804164,"eighty":15.665123,"marketCap":1779993442},{"date":"2025-08-08","current":17.700627,"twenty":4.440923,"median":9.82349,"eighty":15.67238,"marketCap":1703526003},{"date":"2025-08-15","current":17.97186,"twenty":4.440923,"median":9.917298,"eighty":15.726991,"marketCap":1729629785},{"date":"2025-08-22","current":17.975383,"twenty":4.440923,"median":9.97212,"eighty":15.765277,"marketCap":1729968795},{"date":"2025-08-29","current":18.669318,"twenty":4.440923,"median":10.032501,"eighty":15.848057,"marketCap":1796753795},{"date":"2025-09-05","current":18.391039,"twenty":4.437079,"median":10.161405,"eighty":15.873833,"marketCap":1769971993},{"date":"2025-09-12","current":18.229004,"twenty":4.440923,"median":10.244717,"eighty":15.951577,"marketCap":1754377526},{"date":"2025-09-19","current":17.911977,"twenty":4.440923,"median":10.348339,"eighty":16.07924,"marketCap":1723866612},{"date":"2025-09-26","current":17.668924,"twenty":4.440923,"median":10.483035,"eighty":16.238322,"marketCap":1700474912},{"date":"2025-10-03","current":16.622738,"twenty":4.440923,"median":10.565798,"eighty":16.310589,"marketCap":1599788897},{"date":"2025-10-10","current":15.678704,"twenty":4.440923,"median":10.601474,"eighty":16.329708,"marketCap":1508934177},{"date":"2025-10-15","current":15.763245,"twenty":4.440923,"median":10.625534,"eighty":16.329708,"marketCap":1517070421}],"updateTime":1760642692649},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GLP\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2574360138","title":"GLP-1黑馬遞表港股IPO，上輪投後估值5億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2574360138","media":"视频滚动新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574360138?lang=zh_tw&edition=fundamental","pubTime":"2025-10-09 14:25","pubTimestamp":1759991100,"startTime":"0","endTime":"0","summary":"2025年10月8日，诚益生物港股IPO申请获受理。该公司成立于2018年，是临床阶段的全球性生物技术公司，依托TRANDD平台研发新一代口服小分子药物。核心产品口服小分子GLP - 1受体激动剂ECC5004有望成同类最佳。财务上，2023年、2024年及2025年1 - 6月收入分别约3605.9万美元、2.21亿美元、55.7万美元。2023年底完成2500万美元C轮融资，投后估值4.98亿美元。其与阿斯利康合作，阿斯利康已付1.85亿美元预付款及6000万美元里程碑付款。国内超30家企业布局小分子GLP - 1产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/videoroll/2025-10-09/doc-infthnhk9691868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4144","YANG","GLP","HSTECH","BK4590","BK4614"],"gpt_icon":0},{"id":"2572530476","title":"禮來：小分子GLP-1啓動壓力性尿失禁三期臨牀","url":"https://stock-news.laohu8.com/highlight/detail?id=2572530476","media":"医药笔记","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572530476?lang=zh_tw&edition=fundamental","pubTime":"2025-10-04 06:59","pubTimestamp":1759532358,"startTime":"0","endTime":"0","summary":"▎Armstrong2025年10月2日，礼来在Clinicaltrials.gov网站上注册了小分子GLP-1受体激动剂Orforglipron治疗女性压力型尿失禁合并肥胖或超重患者的三期临床试验RESTRAIN-SUI。该三期临床试验计划入组1000例受试者，预计2028年3月完成。Orforglipron已经在糖尿病、肥胖三期临床获得成功，即将递交上市申请，为全球首款小分子GLP-1受体激动剂。礼来围绕Orforglipron积极探索新适应症，陆续启动了高血压、骨关节炎疼痛的三期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251004070023a452afa7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251004070023a452afa7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2023250504.SGD","LU0354030438.USD","LU2491050071.SGD","LU1989771016.USD","SGXZ81514606.USD","LU1093756325.SGD","LU0256863902.USD","LU1232071149.USD","LU2237443382.USD","SG9999015945.SGD","SG9999001176.USD","LU2236285917.USD","LLY","IE0002141913.USD","LU2264538146.SGD","LU0889565916.HKD","LU2461242641.AUD","GLP","LU2087625088.SGD","BK4585","LU0708995401.HKD","LU1061106388.HKD","LU2552382132.HKD","LU0354030511.USD","LU0094547139.USD","LU1712237335.SGD","LU0353189680.USD","LU0432979614.USD","LU2417539215.USD","LU2237443549.SGD","LU2237443465.HKD","LU0471298777.SGD","LU0943347566.SGD","SG9999015986.USD","LU0096364046.USD","LU2471134523.USD","LU0882574055.USD","LU0109394709.USD","LU0640476718.USD","IE00B1BXHZ80.USD","LU1720051017.SGD","SGXZ51526630.SGD","BK4581","IE00BK4W5L77.USD","SGXZ31699556.SGD","LU0471298694.HKD","LU0689472784.USD","LU1127390331.HKD","SGXZ99366536.SGD","LU2491050154.USD"],"gpt_icon":1},{"id":"2572968428","title":"輝瑞收購「Metsera」超長效GLP-1減重新藥「MET-097i」II期臨牀數據亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2572968428","media":"动脉网","labels":["productRelease","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572968428?lang=zh_tw&edition=fundamental","pubTime":"2025-10-04 00:01","pubTimestamp":1759507260,"startTime":"0","endTime":"0","summary":"2025年9月29日，辉瑞旗下Metsera公司公布，其超长效GLP-1受体激动剂候选药物MET-097i在两项IIb期临床试验中取得积极结果，28周每周给药平均体重减轻高达14.1%，个别患者达26.5%，且未出现疗效平台期。此前，9月22日，辉瑞宣布以最高73亿美元总对价收购Metsera，采用“固定预付款+业绩里程碑付款”模式，预付款49亿美元，里程碑付款上限约24亿美元。此次收购是辉瑞在减肥药赛道的“自救”之举，此前辉瑞减肥药研发接连受挫，自研管线陷入困境；而Metsera发展势头强劲，上市后获机构大力支持。消息传出后，Metsera股价单日飙升52%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251004011210a452892b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251004011210a452892b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1894683348.USD","BK4590","LU0122379950.USD","BK4592","LU1291159041.SGD","SG9999001176.SGD","SG9999011175.SGD","BK4533","BK4585","MET","MTSR","LU1989771016.USD","IE00B19Z3B42.SGD","SG9999002232.USD","LU1496350502.SGD","IE00BBT3K403.USD","BK4568","LU0170899867.USD","SG9999013999.USD","LU0225771236.USD","LU1057294990.SGD","LU1066053197.SGD","LU1989772923.USD","BK4599","GLP","BK4144","LU1066051498.USD","LU1883839398.USD","LU1023059063.AUD","LU1989772840.SGD","SG9999002224.SGD","IE000M9KFDE8.USD","BK4007","BK4139","BK4550","LU0306806265.USD","LU0985481810.HKD","LU1894683264.USD","PFE","BK4534","IE0002270589.USD","LU0234572021.USD","IE00BLSP4452.SGD","SG9999003800.SGD","BK4588","SGXZ57979304.SGD","LU0306807586.USD","BK4162","LU0456855351.SGD","SG9999001176.USD"],"gpt_icon":0},{"id":"2571239363","title":"輝瑞(PFE.US)超長效GLP-1兩項減重II期研究取得積極結果","url":"https://stock-news.laohu8.com/highlight/detail?id=2571239363","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571239363?lang=zh_tw&edition=fundamental","pubTime":"2025-09-30 21:24","pubTimestamp":1759238658,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，9月29日，Metsera(MTSR.US)(已被辉瑞(PFE.US)收购)宣布MET-097i的两项减重IIb期研究(VESPER-1和VESPER-13)取得了积极结果。MET-097i是一种同类首创的完全偏向、超长效GLP-1受体激动剂(GLP-1-RA)，具有每月注射1次的给药潜力。Metsera认为，MET-097i可以在稳态下与15mg替尔泊肽的性能相匹敌或超过，并计划在年底之前启动III期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1351522.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0234572021.USD","LU0058720904.USD","IE00BBT3K403.USD","SG9999002232.USD","BK4588","IE0002270589.USD","PFE","LU0122379950.USD","BK4599","BK4144","LU0868494617.USD","LU0306807586.USD","SG9999011175.SGD","SGXZ57979304.SGD","LU0456855351.SGD","BK4534","BK4592","IE00B19Z3B42.SGD","LU0225771236.USD","BK4581","SG9999001176.USD","BK4585","LU0170899867.USD","LU1066051498.USD","LU0321505439.SGD","BK4550","BK4568","IE00B19Z3581.USD","IE000M9KFDE8.USD","IE00BLSP4452.SGD","LU1883839398.USD","SG9999002224.SGD","BK4007","LU0225284248.USD","SG9999013999.USD","LU1894683264.USD","LU0306806265.USD","LU0289739699.SGD","BK4590","LU1066053197.SGD","LU1894683348.USD","BK4533","LU1023059063.AUD","GLP","LU0321505868.SGD","LU0985481810.HKD","SG9999001176.SGD","SG9999003800.SGD","LU1057294990.SGD","IE00BLSP4239.USD"],"gpt_icon":0},{"id":"2572740923","title":"即將被輝瑞收購的Metsera公佈GLP-1候選藥物兩項II期試驗積極結果","url":"https://stock-news.laohu8.com/highlight/detail?id=2572740923","media":"Minhua笔记","labels":["productRelease","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572740923?lang=zh_tw&edition=fundamental","pubTime":"2025-09-30 18:05","pubTimestamp":1759226741,"startTime":"0","endTime":"0","summary":"9月29日，专注减重药物的生物技术公司Metsera公布了其超长效GLP-1受体激动剂MET-097i的两项IIb期研究积极结果，这距离辉瑞同意以最高73亿美元收购Metsera仅一周。此次结果发布强化了辉瑞对Metsera的收购价值，该交易于9月22日宣布，前期款49亿美元，外加潜在里程碑付款24亿美元，总额最高73亿美元。交易预计于2025年第四季度完成，标志着辉瑞重返减重药物市场，旨在通过Metsera的创新管线与礼来和诺和诺德竞争。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250930191303a6a85010&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250930191303a6a85010&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999001176.SGD","IE000M9KFDE8.USD","LU0321505439.SGD","LU0122379950.USD","BK4144","BK4590","IE00BBT3K403.USD","LU0225771236.USD","LU1057294990.SGD","LU1066051498.USD","LU1023059063.AUD","LU0985481810.HKD","SG9999003800.SGD","LU0456855351.SGD","BK4599","GLP","BK4568","IE0002270589.USD","LU0868494617.USD","PFE","LU0306806265.USD","BK4585","LU1066053197.SGD","IE00B19Z3581.USD","LU1894683348.USD","SG9999002232.USD","BK4581","LU0321505868.SGD","LU0225284248.USD","BK4534","SG9999013999.USD","LU0170899867.USD","LU1883839398.USD","SGXZ57979304.SGD","LU1894683264.USD","SG9999011175.SGD","LU0058720904.USD","SG9999001176.USD","LU0306807586.USD","SG9999002224.SGD","IE00BLSP4452.SGD","MTSR","BK4139","BK4550","LU0289739699.SGD","LU0234572021.USD","BK4592","BK4007","BK4533","IE00B19Z3B42.SGD"],"gpt_icon":1},{"id":"2570907071","title":"開源證券：小核酸藥物有望成為減重賽道新風口 聯用GLP-1或多重滿足臨牀需求","url":"https://stock-news.laohu8.com/highlight/detail?id=2570907071","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570907071?lang=zh_tw&edition=fundamental","pubTime":"2025-09-26 14:20","pubTimestamp":1758867619,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，开源证券发布研报称，小核酸药物布局减重适应症主要围绕INHBE和ALK7两个靶点。小核酸药物联用GLP-1，有望解决多重未满足临床需求临床前大鼠数据显示，Arrowhead的ALK7siRNA分子联用Tirzepatide可以进一步提升减重效果的同时，还有望带来更持久的疗效，从而实现更长间隔的给药。这提示INHBE/ALK7通路在脂肪分布而非单纯体重调控中起着关键作用。风险提示创新药研发热度下滑、药物临床研发失败、药物安全性风险等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1349792.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B031HY20.USD","LU1807302812.USD","BK1521","GLP","LU0880133367.SGD","IE0008369823.USD","LU0359202008.SGD","IE00BZ08YR35.GBP","LU1152091168.USD","LU1226287792.SGD","SG9999004220.SGD","LU0067412154.USD","LU1328277881.USD","BK1191","LU1960683339.HKD","IE0008368742.USD","LU2543165471.USD","LU0359201612.USD","LU1226287529.USD","IE00BZ08YS42.EUR","01276","LU0072913022.USD","LU0315179316.USD","IE00B5MMRT66.SGD","LU1008478684.HKD","LU1226288253.USD","BK1515","LU1023057109.AUD","01093","LU1152091754.HKD","LU1951186391.HKD","LU0326950275.SGD","BK4144","LU0359201885.HKD","IE00B543WZ88.USD","LU1993786604.SGD","LU1226288170.HKD","LU1813983027.USD","LU0314109678.HKD","BK4590","161027","LU0140636845.USD","LU2039709279.SGD","LU1226287875.USD","IE00BZ08YT58.USD","LU0501845795.SGD"],"gpt_icon":0},{"id":"2569997709","title":"諾和諾德、禮來強勢領跑，恆瑞、信達如何突圍GLP-1紅海？","url":"https://stock-news.laohu8.com/highlight/detail?id=2569997709","media":"E药经理人","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569997709?lang=zh_tw&edition=fundamental","pubTime":"2025-09-24 19:49","pubTimestamp":1758714542,"startTime":"0","endTime":"0","summary":"在全球市场中，诺和诺德、礼来、阿斯利康等跨国巨头凭借领先的创新药管线与强大的商业化能力，持续占据主导地位。2025年上半年,全球 GLP-1 市场规模达到 352 亿美元,预计全年超过700亿美元，增幅预计超过 40%。本土企业如恒瑞医药、华东医药、信达生物等，正通过自主研发、License-in合作等方式加速布局 GLP-1、SGLT-2 等高潜力赛道，逐步打破外资垄断格局。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250924195605a4410cba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250924195605a4410cba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4581","LU2461242641.AUD","LU0256863811.USD","IE00B4R5TH58.HKD","LLY","LU0097036916.USD","LU0238689110.USD","LU0466842654.USD","LU2237443382.USD","LU2237443549.SGD","LU2237443978.SGD","BK4534","LU0471298694.HKD","LU0786609619.USD","LU2023250504.SGD","LU2360106947.USD","LU0820561909.HKD","IE00BJJMRZ35.SGD","BK4533","IE00BJT1NW94.SGD","LU2491050154.USD","01801","LU2237443895.HKD","LU2265009873.SGD","LU2491050071.SGD","NVO","LU2357305700.SGD","01276","BK4532","LU2468319806.SGD","LU0109391861.USD","GLP","BK4516","LU2089984988.USD","LU1064131342.USD","LU0323591593.USD","LU0640476718.USD","BK4590","LU0289739699.SGD","LU1267930730.SGD","GB00BDT5M118.USD","LU0689472784.USD","LU1093756325.SGD","LU2491049909.HKD","LU2237443622.USD","LU0198837287.USD","IE00B1BXHZ80.USD","LU1366192091.USD","LU0456855351.SGD","LU0256863902.USD","LU1093756168.USD","LU1280957306.USD"],"gpt_icon":1},{"id":"2569747572","title":"諾和諾德全球首款口服GLP-1減重藥療效數據刷新紀錄","url":"https://stock-news.laohu8.com/highlight/detail?id=2569747572","media":"美通社头条","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569747572?lang=zh_tw&edition=fundamental","pubTime":"2025-09-24 08:02","pubTimestamp":1758672124,"startTime":"0","endTime":"0","summary":"在此项为期64周的试验中，口服司美格鲁肽片25mg联合生活方式干预，在307名肥胖或超重且伴有至少一种体重相关合并症但无糖尿病的成人患者中与安慰剂进行了对比。在不考虑患者依从性的情况下评估疗效时，口服司美格鲁肽片25 mg组患者仍然实现了13.6%的平均体重降幅，而安慰剂组这一数字则为2.2%。这些发现与此前进行的Wegovy注射液各项试验结果一致。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250924081146a43fa68e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250924081146a43fa68e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","NVO","LU0154236417.USD","LU1093756325.SGD","LU1093756168.USD","BK4585","BK4007","BK4144","GLP","IE00BKVL7J92.USD","BK4590","BK4532","IE00BZ1G4Q59.USD","BK4588"],"gpt_icon":1},{"id":"2569747389","title":"警惕GLP-1「陷阱」","url":"https://stock-news.laohu8.com/highlight/detail?id=2569747389","media":"医曜","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569747389?lang=zh_tw&edition=fundamental","pubTime":"2025-09-24 07:59","pubTimestamp":1758671992,"startTime":"0","endTime":"0","summary":"随着辉瑞收购GLP-1减肥药开发商Metsera消息的传出，GLP-1药物下半场的竞争愈发激烈。对于GLP-1原料药企业而言，这段时间是名副其实的黄金时代。截至目前，已有药明康德、诺泰生物、翰宇药业、圣诺生物、泰德医药等超10家国内药企业务涉及GLP-1原料药供应。礼来双靶点药物替尔泊肽的强势崛起，正在改写GLP-1市场格局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8mtxpgAIhs4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["BK4590","BK4144","GLP"],"gpt_icon":0},{"id":"2569916793","title":"攪局GLP-1減肥藥，輝瑞砸超70億美元買下一家上市公司，諾和諾德、禮來又有新對手","url":"https://stock-news.laohu8.com/highlight/detail?id=2569916793","media":"时代财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569916793?lang=zh_tw&edition=fundamental","pubTime":"2025-09-23 16:46","pubTimestamp":1758617175,"startTime":"0","endTime":"0","summary":"另有两种口服GLP-1 RA候选药物，预计将很快开始临床试验；此外还拥有其他临床前营养刺激激素疗法。由于安全性问题待解，辉瑞经多方考虑后决定终止开发这一小分子药物。公开信息显示，辉瑞称，“肥胖药物是公司应对80亿美元专利危机的潜力增长点”。而随着诺和诺德和礼来制药等巨头在GLP-1领域的竞争升级，辉瑞能否凭借此次收购重新杀入GLP-1赛道并占有一席之地，仍是未知数。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250923165108a73137a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250923165108a73137a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0882574055.USD","LU0985481810.HKD","LU0097036916.USD","LU2417539215.USD","LU0456855351.SGD","LU1366192091.USD","IE00BLSP4452.SGD","BK4590","LU0094547139.USD","IE0002141913.USD","IE00BK4W5M84.HKD","NVO","IE00BLSP4239.USD","LU0432979614.USD","LU1720051017.SGD","LU1894683348.USD","LU2236285917.USD","SGXZ81514606.USD","LU0353189680.USD","LU1623119135.USD","LU0096364046.USD","BK4516","LU0320765992.SGD","LU0786609619.USD","PFE","SG9999001176.SGD","IE00B19Z3B42.SGD","LU0889565916.HKD","LU1983299246.USD","LU1232071149.USD","LU0316494557.USD","LU0306806265.USD","LU2750360997.AUD","LU0170899867.USD","LU0672654240.SGD","LU0354030511.USD","BK4581","LU0353189763.USD","SG9999014914.USD","GLP","SG9999018857.SGD","LU1868837300.USD","LU0234572021.USD","LU0323591593.USD","BK4533","LU2265009873.SGD","LU1064131342.USD","LU0320765059.SGD","IE00BJT1NW94.SGD"],"gpt_icon":1},{"id":"2569763223","title":"港股異動 | 派格生物醫藥-B(02565)午前漲超5% GLP-1多靶點領域臨牀進度靠前 PB-718為公司旗下重磅品種","url":"https://stock-news.laohu8.com/highlight/detail?id=2569763223","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569763223?lang=zh_tw&edition=fundamental","pubTime":"2025-09-23 11:52","pubTimestamp":1758599567,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，派格生物医药-B午前涨超5%，该股上市至今股价累计涨幅逾3.1倍。同时，上述部分MNC在GLP-1领域的技术路径、新靶点、新适应症等方面的布局仍有较大提升空间，该行看好国内细分领域布局药企出海BD机遇。浙商证券认为，在GLP-1多靶点领域国内部分管线临床进度靠前，有望持续诞生大BD事件。据了解，PB-718为派格生物医药旗下重磅产品，该药物是一款新型长效GLP-1/GCG双受体激动剂，其核心治疗方向是MASH治疗领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1348339.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4614","HSCEI","YANG","161726","02565","GLP","BK4211","PB","399441","BK1161","BK4590","BK4144"],"gpt_icon":1},{"id":"2569786759","title":"諾和諾德：GLP-1/GIP/Amylin三靶點激動劑啓動二期臨牀","url":"https://stock-news.laohu8.com/highlight/detail?id=2569786759","media":"医药笔记","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569786759?lang=zh_tw&edition=fundamental","pubTime":"2025-09-23 07:54","pubTimestamp":1758585288,"startTime":"0","endTime":"0","summary":"▎Armstrong2025年9月22日，诺和诺德在Clinicaltrials.gov网站上注册了NNC0662-0419用于减重的二期临床试验。该二期临床试验计划入组220例肥胖或超重受试者，预计2026年底完成。根据临床试验注册信息和官网信息，NNC0662-0419应为GLP-1/GIP/Amylin三靶点激动剂，应为NN9662。诺和诺德布局了两款三靶点激动剂，包括自研的GLP-1/GIP/Amylin，以及从联邦制药引进的GLP-1/GIP/GCG。总结诺和诺德司美格鲁肽为目前最畅销的GLP-1，但受到替尔泊肽的强势冲击，GLP-1+Amylin、GLP-1/Amylin正在积极推进，再后续的迭代产品即为三靶点激动剂，减重疗效不断强化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250923080959a43d4d3a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250923080959a43d4d3a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756168.USD","BK4007","BK4532","BK4599","BK4144","LU1093756325.SGD","BK4590","NVO","LU0154236417.USD","BK4585","IE00BZ1G4Q59.USD","BK4588","GLP","IE00BKVL7J92.USD"],"gpt_icon":1},{"id":"2569787493","title":"信達生物：減肥藥瑪仕度肽獲批糖尿病適應症 為全球首個GCG/GLP-1雙受體激動降糖藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2569787493","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569787493?lang=zh_tw&edition=fundamental","pubTime":"2025-09-22 21:07","pubTimestamp":1758546464,"startTime":"0","endTime":"0","summary":"本报讯（记者金婉霞）9月19日，信达生物制药（苏州）有限公司（以下简称“信达生物”）宣布公司产品玛仕度肽注射液第二项适应症获得国家药监局批准，用于成人2型糖尿病患者的血糖控制。这是继今年6月获批减重适应症后，该药物的第二个获批适应症。记者从企业获悉，本次获批的玛仕度肽注射笔采用隐藏式针头设计、为一次性使用装置，还采用了X切面技术，可减轻注射疼痛。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202509223520063044.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2242644610.SGD","BK4144","LU2328871848.SGD","LU0455707207.USD","LU2097828714.EUR","LU1969619763.USD","BK4590","01801","GLP","LU2097828805.USD","LU2097828631.EUR","BK1589","LU2097828557.USD","BK1161","BK1583","LU2097828474.EUR","LU0502904849.HKD","LU2488822045.USD"],"gpt_icon":0},{"id":"2569202096","title":"中國生物製藥(01177)：TQF3250膠囊「GLP-1受體激動劑」臨牀試驗申請獲NMPA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2569202096","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569202096?lang=zh_tw&edition=fundamental","pubTime":"2025-09-22 16:37","pubTimestamp":1758530264,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，本集团自主研发的国家1类创新药TQF3250胶囊“GLP-1受体激动剂”的新药临床试验申请已获得中国国家药品监督管理局受理，拟用于治疗2型糖尿病。目前，全球仅一款口服GLP-1RA获批上市。本集团将加快推进TQF3250的临床开发，为2型糖尿病患者提供更便捷、高效的治疗方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1347909.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01177","GLP","BK1521","BK1191","BK4590","BK4144","IE00BZ08YS42.EUR","BK1515","BK1589","IE00BZ08YT58.USD","IE00BZ08YR35.GBP"],"gpt_icon":0},{"id":"2569752502","title":"繼 GLP-1 之後，小核酸接棒，有望開啓千億減重賽道「第二增長曲線」","url":"https://stock-news.laohu8.com/highlight/detail?id=2569752502","media":"医麦客","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569752502?lang=zh_tw&edition=fundamental","pubTime":"2025-09-22 07:20","pubTimestamp":1758496825,"startTime":"0","endTime":"0","summary":"这背后逻辑已然清晰：在 GLP-1 类药物全球销售额即将突破 500 亿美元、市场趋于饱和的背景下，行业正加速寻找“下一个增长极”。而小核酸疗法凭借“源头沉默、超长效、机制互补”优势，已成为减重赛道的核心突破口。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250922072551a72df42b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250922072551a72df42b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","BK4588","NVO","IE00BZ1G4Q59.USD","BK4144","BK4599","LU1093756325.SGD","BK4585","IE00BKVL7J92.USD","LU0154236417.USD","BK4007","LU1093756168.USD","BK4590","GLP"],"gpt_icon":1},{"id":"2568620214","title":"信達生物：瑪仕度肽獲批2型糖尿病治療許可，GLP-1類藥物開啓適應症擴容競爭","url":"https://stock-news.laohu8.com/highlight/detail?id=2568620214","media":"红星资本局","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568620214?lang=zh_tw&edition=fundamental","pubTime":"2025-09-20 17:53","pubTimestamp":1758362018,"startTime":"0","endTime":"0","summary":"红星资本局9月20日消息9月19日晚间，信达生物（01801.HK）公告称，旗下自研药物玛仕度肽注射液获批2型糖尿病治疗许可。今年6月，玛仕度肽减重适应症已经获批，至此，首款国产自研GLP-1类药补齐“减重和控糖”两大核心适应症。红星资本局注意到，目前GLP-1类药竞争环境已经发生变化，传统GLP-1类药巨头已开始在适应症扩容上做文章。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202509203519046937.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4590","BK4144","LU2097828714.EUR","BK1583","BK1161","01801","LU1969619763.USD","LU2242644610.SGD","LU2097828631.EUR","GLP","LU2097828474.EUR","BK1589","LU0455707207.USD","LU0502904849.HKD","LU2097828805.USD","LU2097828557.USD","LU2488822045.USD","LU2328871848.SGD"],"gpt_icon":1},{"id":"2568566012","title":"減重藥巨頭在口服藥上拼數據：禮來宣佈自研GLP-1製劑降糖、減重效果優於口服司美格魯肽","url":"https://stock-news.laohu8.com/highlight/detail?id=2568566012","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568566012?lang=zh_tw&edition=fundamental","pubTime":"2025-09-19 16:57","pubTimestamp":1758272267,"startTime":"0","endTime":"0","summary":"近日，礼来公司公布了在研口服小分子GLP-1RA（胰高血糖素样肽‐1受体激动剂）药物“orforglipron”的Ⅲ期临床研究“ACHIEVE-3”的顶线结果。该结果显示，orforglipron的降糖效果显著优于口服司美格鲁肽。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202509193518484917.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202509193518484917.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GLP","SG9999013999.USD","LU1868837300.USD","LU0354030438.USD","LU0234572021.USD","LU0823434583.USD","LU2087625088.SGD","LU0006306889.USD","SGXZ99366536.SGD","LU2471134523.USD","LLY","LU0106261372.USD","BK4588","LU1868836757.USD","SG9999018857.SGD","SG9999014906.USD","SG9999015945.SGD","LU0114720955.EUR","LU2471134879.HKD","LU1868836914.USD","LU0109394709.USD","LU1548497426.USD","LU1069344957.HKD","LU1814569148.SGD","LU1868837136.USD","SG9999001176.USD","LU1057294990.SGD","IE0002141913.USD","LU0096364046.USD","LU1868836591.USD","LU0882574055.USD","LU1061106388.HKD","LU0823434740.USD","SG9999015952.SGD","LU2264538146.SGD","LU2750360997.AUD","LU0943347566.SGD","LU2471134796.USD","LU2106854487.HKD","LU0354030511.USD","LU2750360641.GBP","SG9999014898.SGD","LU0672654240.SGD","SGXZ51526630.SGD","LU0471298777.SGD","BK4599","SGXZ57979304.SGD","LU1720051108.HKD","SG9999018865.SGD","LU2552382132.HKD"],"gpt_icon":1},{"id":"2568832236","title":"Grvt 完成 1900 萬美元 A 輪孖展，投資方包括 ZKsync、Further Ventures、EigenCloud 等，引領隱私優先的鏈上金融，開啓萬億美元市場新篇章","url":"https://stock-news.laohu8.com/highlight/detail?id=2568832236","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568832236?lang=zh_tw&edition=fundamental","pubTime":"2025-09-19 11:10","pubTimestamp":1758251400,"startTime":"0","endTime":"0","summary":"基于零知识证明技术的链上隐私去中心化交易平台 Grvt，今日宣布完成 1900 万美元 A 轮融资。本轮融资由 Grvt 的核心技术合作伙伴 ZKsync 与总部位于阿布扎比的资本市场基础设施投资公司 Further Ventures 共同领投。Further Ventures 曾于去年 12 月主导了 Grvt 的战略投资轮。作为阿布扎比战略布局区块链的重要投资部门，Further Ventures 的领投地位进一步巩固了其在全球链上金融发展中的关键作用。Grvt 并非受监管实体，用户资金不受监管保护。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info/news/59675","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_zh_highlight","symbols":["ETHW","BK4099","ETHU","ETHV","BK4601","OP.USD.HKCC","CETH","GLP","ETH","ETH.USD.HKCC","BK4585","QETH","BK4144","ETHE","BK4590","BK4588","EZET","LDO.USD.HKCC","ETH.USD.CC","BK4594","FETH"],"gpt_icon":1},{"id":"1190486588","title":"GLP-1藥物使用或推動能量飲料銷售增長","url":"https://stock-news.laohu8.com/highlight/detail?id=1190486588","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190486588?lang=zh_tw&edition=fundamental","pubTime":"2025-09-19 01:20","pubTimestamp":1758216028,"startTime":"0","endTime":"0","summary":"Stifel分析师基于消费者调查数据表示，GLP-1药物的广泛使用可能带动能量饮料销售增长。调查结果显示，使用GLP-1药物的受访者每月至少消费一次能量饮料的可能性比普通人群高出42%。\n分析师指出：\"我们认为这反映了对更多咖啡因的需求，因为GLP-1药物导致的食欲下降减少了可转化为能量的卡路里摄入。\"\n分析师表示，GLP-1药物可获得性的提高，特别是在18至34岁年龄段人群中的普及——这一年龄段正是能量饮料消费最多的群体——可能有利于能量饮料销售。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLP","BK4590","BK4144"],"gpt_icon":0},{"id":"2568844975","title":"禮來小分子GLP-1：減重不及預期，降糖為何擊敗司美格魯肽","url":"https://stock-news.laohu8.com/highlight/detail?id=2568844975","media":"医药笔记","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568844975?lang=zh_tw&edition=fundamental","pubTime":"2025-09-18 08:13","pubTimestamp":1758154429,"startTime":"0","endTime":"0","summary":"2025年9月16日， 礼来 小分子GLP-1受体激动剂Orforglipron减重三期临床ATTAIN-1数据发表在新英格兰期刊上，36mg高剂量组治疗72周减重12.4%，安慰剂校正后减重幅度为11.5%。可见，礼来小分子GLP-1受体激动剂Orforglipron的减重疗效不及司美格鲁肽。2025年9月17日，礼来公布Orforglipron治疗二型糖尿病三期临床ACHIEVE-3数据，36mg高剂量组治疗52周HbA1c降低2.2%，14mg口服司美格鲁肽降低1.4%，Orforglipron头对头击败司美格鲁肽。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250918082742a4cc8399&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250918082742a4cc8399&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999015978.USD","LU0823416689.USD","LU0889565916.HKD","LU2552382132.HKD","SGXZ51526630.SGD","LU1093756168.USD","LU2468319806.SGD","LU0353189680.USD","LU0097036916.USD","LU0672654240.SGD","LU0256863902.USD","LU1057294990.SGD","SG9999017495.SGD","IE0002141913.USD","LU1064131342.USD","BK4599","LU0058720904.USD","IE00B2B36J28.USD","IE00B1BXHZ80.USD","IE0009355771.USD","LU0079474960.USD","LU1868837300.USD","LU0109391861.USD","LU1035775433.USD","LU2461242641.AUD","SG9999014914.USD","LU2361044949.HKD","LU1551013342.USD","LU2237443622.USD","LU0096364046.USD","LU0432979614.USD","LU2112291526.USD","LU2750360641.GBP","LLY","LU1868837136.USD","LU0320765992.SGD","LU0471298694.HKD","LU0823434583.USD","LU2471134952.CNY","LU2746668461.USD","LU2456880835.USD","SGXZ57979304.SGD","IE0004445239.USD","LU1868836914.USD","LU0114720955.EUR","IE00BKVL7J92.USD","GLP","BK4007","NVO","LU0823434740.USD"],"gpt_icon":1}],"pageSize":20,"totalPage":8,"pageCount":1,"totalSize":147,"code":"91000000","status":"200"}]}}